Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01885052 · ClinicalTrials.gov registry record · Phase 2
Evaluation of National Cancer Institute Young Adult Stop-Smoking Program
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 4,432
- Enrollment target
NCT01885052: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01885052 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 4,432 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (3232% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01885052, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4,432 participants
- Enrollment target
Study Summary
Background: \- Researchers want to see how well the QuitTXT text-message program helps smokers ages 18 29 stop smoking. This is part of a larger online stop-smoking program by the National Cancer Institute. The QuitTXT program is a 2-week countdown to the smoker s quit date with 6 weeks of follow-up messages. Program participants will receive texts on their cell phones, including tips, information, and motivational messages, and then fill out surveys. Objectives: \- To study how well the QuitTXT program helps smokers ages 18 29 stop smoking. Eligibility: \- Adults ages 18 29 who have smoked on at least 5 of the past 30 days and who want to stop smoking in the next 30 days. Design: * Participants will receive a certain number of text messages during the 8-week study. They will receive between 0 to 5 messages per day (or up to a total of 130 messages). * Participants will first fill out a survey about their smoking and quitting experiences. Then they will choose a date to quit smoking (a quit date ) between 2 and 3 weeks after this survey. * Participants will take four other surveys online, one during the program and three more after they ve completed the program. Each survey will take about 10 20 minutes and asks about their smoking habits and views on smoking and quitting. Each survey will be sent by email, with reminders sent by email or telephone. * Participants will receive an iTunes or Amazon gift card for completing each survey honestly.
Interventions
- BEHAVIORAL QuitTXT Study
- BEHAVIORAL Low Contact
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,432 participants |
| Start Date | 2013-06-12 |
| Est. Completion | 2015-05-28 |
| Phase | Phase 2 |
What the finished NCT01885052 record still lists
NCT01885052 is an interventional study that assigns participants to a tested intervention. Its 4,432 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (3232% higher).
The record links to 0 conditions, and to 2 interventions - of which QuitTXT Study is the first listed.
NCT01885052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01885052 about?
NCT01885052 is a clinical study titled "Evaluation of National Cancer Institute Young Adult Stop-Smoking Program". Background: \- Researchers want to see how well the QuitTXT text-message program helps smokers ages 18 29 stop smoking. This is part of a larger online stop-smoking program by the National Cancer Institute. The QuitTXT program is a 2-week countdown to the smoker s quit date with 6 weeks of follow-u...
What is the current status of trial NCT01885052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4,432 participants. The study started on 2013-06-12. Estimated completion is 2015-05-28.
What interventions are being tested in trial NCT01885052?
The interventions under investigation include: QuitTXT Study (BEHAVIORAL), Low Contact (BEHAVIORAL).
Who is sponsoring clinical trial NCT01885052?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01885052's enrollment target sits among peer trials
4,432 2nd of 2000 the highest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02660645 · 4,400 participants
Blue Light Cystoscopy With Cysview® Registry
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
- NCT06252753 · 4,490 participants
Observational Study Protocol: LIVER-R
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI